Voyager Therapeutics (VYGR) Leases (2019 - 2026)

Voyager Therapeutics' Leases history runs 8 years deep, the most recent figure standing at $27.2 million for Q1 2026.

• In Q1 2026, Leases fell 15.31% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $27.2 million (down 15.31% YoY), while the FY2025 annual figure was $28.5 million, down 14.61% from the prior year.
• Leases came in at $27.2 million for Q1 2026 at Voyager Therapeutics, down from $28.5 million in the prior quarter.
• In the past five years, Leases ranged from a high of $39.2 million in Q1 2024 to a low of $13.5 million in Q4 2023.
• A 5-year average of $25.2 million and a median of $28.5 million in 2025 frame the typical range for Leases.
• Across the five-year window, Leases tumbled 53.72% in 2022 and jumped 161.08% in 2024, its largest moves.
• Voyager Therapeutics' Leases stood at $15.5 million in 2022, then declined by 12.75% to $13.5 million in 2023, then surged by 146.85% to $33.3 million in 2024, then decreased by 14.61% to $28.5 million in 2025, then fell by 4.46% to $27.2 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $27.2 million, $28.5 million, and $29.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison